Due to its over-expression on almost all types of epithelial tumor tissues, the tumor-associated mucin MUC 1 is an attractive target antigen for a cancer immunotherapy. However, there also some problems to be solved. The first problem is tumor specific antigen. MUC1 is a member of transmembrane glycoprotein family, mucin. In normal tissues, MUC1 expresses on the free face of epithelial cells and complex glycosylated. But in tumor tissue, MUC1 protein over-expresses on all the faces of epithelial cells and specifically glycosylated, such as Tn, T, Sialyl-Tn and Sialyl-T due to alteration of enzyme activity. So 20-mer extracellular repeat glycopeptide sequence of MUC1 is an excellent target of vaccine development. The next problem is vaccine systems. Short peptides are always poor immunogenic, so vaccine systems are necessary to increase the immunogenicity of MUC1 glycopeptides. We synthesized MUC1 glycopeptides by solid-phase peptide synthesis with glycosylated threonines and serines as building blocks. And several systems were developed to load antigens. The first system is conjugates of glycopeptides and bovine serum albumin (BSA). This carrier protein elicited high level of antibodies1 . To simplify the structure, we conjugated T cell epitope or Toll-like receptor ligand to MUC1 glycopeptides, this kind of vaccines also elicited immune response23 . To simulate multivalent structure, we designed self-assembling vaccines, which aggregated in neutral condition and elicited immune system4 .